Anixa Biosciences (STU:CY71) Cyclically Adjusted Book per Share: €0.54 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CY71 Anixa Biosciences Inc STU:CY71
36 GF Score
Price €2.76
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Cyclically Adjusted Book per Share?

Anixa Biosciences STU:CY71 +3.18% 36 Cyclically Adjusted Book per Share is €0.54 as of Apr. 2026. GuruFocus rates STU:CY71 with a GF Score™ of 36/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Anixa Biosciences's adjusted book value per share for the three months ended in Apr. 2026 was €0.365. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.54 for the trailing ten years ended in Apr. 2026.

During the past 12 months, Anixa Biosciences's average Cyclically Adjusted Book Growth Rate was 1.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 15.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 28.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Anixa Biosciences was 39.20% per year. The lowest was -27.00% per year. And the median was -7.50% per year.

As of today (2026-07-15), Anixa Biosciences's current stock price is €2.76. Anixa Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2026 was €0.54. Anixa Biosciences's Cyclically Adjusted PB Ratio of today is 5.11.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Anixa Biosciences was 34.85. The lowest was 1.50. And the median was 10.13.


Anixa Biosciences  (STU:CY71) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Anixa Biosciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.76/0.54
=5.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Anixa Biosciences was 34.85. The lowest was 1.50. And the median was 10.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Anixa Biosciences Cyclically Adjusted Book per Share Related Terms


Anixa Biosciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Cyclically Adjusted Book per Share Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.41 0.50 0.59 0.53

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.55 0.53 0.53 0.54

STU:CY71 vs BMEA, PMN, ATRA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Anixa Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Cyclically Adjusted PB Ratio falls into.


STU:CY71
36GF Score
Anixa Biosciences Inc STU:CY71
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anixa Biosciences's adjusted Book Value per Share data for the three months ended in Apr. 2026 was:

Adj_Book= Book Value per Share /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=0.365/333.0200*333.0200
=0.365

Current CPI (Apr. 2026) = 333.0200.

Anixa Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201607 0.160 240.628 0.221
201610 0.092 241.729 0.127
201701 -0.373 242.839 -0.512
201704 0.286 244.524 0.390
201707 0.315 244.786 0.429
201710 0.406 246.663 0.548
201801 0.317 247.867 0.426
201804 0.293 250.546 0.389
201807 0.290 252.006 0.383
201810 0.250 252.885 0.329
201901 0.247 251.712 0.327
201904 0.291 255.548 0.379
201907 0.257 256.571 0.334
201910 0.233 257.346 0.302
202001 0.235 257.971 0.303
202004 0.226 256.389 0.294
202007 0.317 259.101 0.407
202010 0.307 260.388 0.393
202101 0.427 261.582 0.544
202104 1.000 267.054 1.247
202107 1.030 273.003 1.256
202110 1.017 276.589 1.224
202201 0.996 281.148 1.180
202204 0.988 289.109 1.138
202207 1.017 296.276 1.143
202210 0.954 298.012 1.066
202301 0.834 299.170 0.928
202304 0.790 303.363 0.867
202307 0.744 305.691 0.811
202310 0.740 307.671 0.801
202401 0.711 308.417 0.768
202404 0.688 313.548 0.731
202407 0.624 314.540 0.661
202410 0.570 315.664 0.601
202501 0.536 317.671 0.562
202504 0.444 320.795 0.461
202507 0.433 323.048 0.446
202510 0.394 0.000
202601 0.383 325.252 0.392
202604 0.365 333.020 0.365

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.54 mean?
Anixa Biosciences (STU:CY71) has a Cyclically Adjusted Book per Share of €0.54 as of Apr. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' Cyclically Adjusted Book per Share too high?
Anixa Biosciences' current Cyclically Adjusted Book per Share is €0.54. Overall, Anixa Biosciences has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Cyclically Adjusted Book per Share compare to BMEA and PMN?
Anixa Biosciences' Cyclically Adjusted Book per Share of €0.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Cyclically Adjusted Book per Share is €0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (STU:CY71) has a current Cyclically Adjusted Book per Share of €0.54. The current Cyclically Adjusted Book per Share is €0.54. Anixa Biosciences' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Anixa Biosciences (STU:CY71), the current Cyclically Adjusted Book per Share is €0.54 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges ANIX:USA
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
36GF Score

Get the complete analysis for STU:CY71

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.76
Price